Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
J Senapati, E Jabbour, H Kantarjian, NJ Short - Leukemia, 2023 - nature.com
The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …
been a model for cancer therapy development. Though most patients with CML have a …
Blast and accelerated phase CML: room for improvement
J How, V Venkataraman, GS Hobbs - Hematology, 2021 - ashpublications.org
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia
(CML). With TKI therapy, the percentage of patients who progress to accelerated phase (AP) …
(CML). With TKI therapy, the percentage of patients who progress to accelerated phase (AP) …
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients
BACKGROUND Outcomes in patients with chronic myeloid leukemia in blast phase (CML‐
BP) are historically dismal. Herein, the authors sought to analyze the characteristics …
BP) are historically dismal. Herein, the authors sought to analyze the characteristics …
Chronic myeloid leukemia: overview of new agents and comparative analysis
Opinion statement Discovery of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI) in
the therapy of patients with chronic myeloid leukemia (CML) is perhaps the most popular …
the therapy of patients with chronic myeloid leukemia (CML) is perhaps the most popular …
Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia
Simple Summary Chronic myeloid leukaemia (CML) is a type of blood cancer that is
currently well-managed with drugs that target cancer-causing proteins. However, a …
currently well-managed with drugs that target cancer-causing proteins. However, a …
Management of chronic myeloid leukemia in advanced phase
M Bonifacio, F Stagno, L Scaffidi, M Krampera… - Frontiers in …, 2019 - frontiersin.org
Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
G Rosti, F Castagnetti, G Gugliotta… - Nature reviews clinical …, 2017 - nature.com
The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …
Educational session: managing chronic myeloid leukemia as a chronic disease
A Hochhaus - Hematology 2010, the American Society of …, 2011 - ashpublications.org
Elucidation of the pathogenesis of chronic myeloid leukemia (CML) and the introduction of
tyrosine kinase inhibitors (TKIs) has transformed this disease from being invariably fatal to …
tyrosine kinase inhibitors (TKIs) has transformed this disease from being invariably fatal to …
[PDF][PDF] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence.
R Çiftçiler, IC Haznedaroglu - European Review for Medical & …, 2021 - europeanreview.org
Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is a neoplastic
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-
chronic phase (CP) are associated with improved outcome. We analyzed the impact of such …
chronic phase (CP) are associated with improved outcome. We analyzed the impact of such …